Diagnosis, treatment and clinical perspectives of acromegaly

Ferdinand Roelfsema*, Gerrit van den Berg

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review


    Acromegaly is an insidious disease of the pituitary caused by a growth hormone-secreting adenoma. Generally, the diagnosis is made rather late in the course of the disease. Currently, acromegaly can be cured in about half of the patients with the disease by expert surgery. The remainder of non-surgically cured patients often can be effectively treated with somatostatin analogs; either with the new generation of dopaminergic drugs or with Pegvisomant, a GHreceptor blocking agent. However, at the time of diagnosis many patients suffer from serious comorbidities, including hypertension, heart disease, arthrosis, sleep apnea and diabetes mellitus. Recent reports have shown that mortality risk can be normalized. Nevertheless, all efforts should be undertaken to treat comorbidities. New strategies for surgery and medical treatment are discussed.

    Original languageEnglish
    Pages (from-to)619-644
    Number of pages26
    JournalExpert review of endocrinology & metabolism
    Issue number6
    Publication statusPublished - 2015


    • acromegaly
    • pituitary
    • growth hormone
    • TSH
    • hormone rhythms
    • somatostatin analogs
    • pegvisomant
    • pituitary surgery
    • mortality
    • joints

    Cite this